SCHEMBL2366019

SCHEMBL2366019

Cc1cnc(N2CCN(C(=O)c3ccc(N4CCOC4=O)cc3F)CC2)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.43
KMT2A Q03164 1/20 0.43
LMNA P02545 6/20 0.41
MAPT P10636 3/20 0.41
TSHR P16473 1/20 0.41
TP53 P04637 6/20 0.41
KDM4E B2RXH2 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.39
THRB P10828 2/20 0.37
CPS1 P31327 1/20 0.37
GBA1 P04062 1/20 0.37
TOP2B Q02880 1/20 0.36
CMA1 P23946 1/20 0.36
SLC6A9 P48067 1/20 0.36
SLC6A5 Q9Y345 1/20 0.36
ALDH1A1 P00352 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2365724 0.92 LMNA (0.43) HTTKMT2ALMNAMAPTTP53
SCHEMBL2366011 0.91 LMNA (0.42) HTTKMT2ALMNAMAPTTSHR
SCHEMBL2366227 0.90 TP53 (0.40) HTTKMT2ALMNAMAPTTP53
SCHEMBL2366126 0.89 KMT2A (0.40) HTTKMT2ALMNAMAPTTP53
SCHEMBL12240539 0.89 HTT (0.40) HTTKMT2ALMNAMAPTTSHR
SCHEMBL2366595 0.89 HTT (0.42) HTTKMT2ALMNAMAPTTP53
Hydrochloric Acid SCHEMBL2365824 0.88 HTT (0.39) HTTKMT2ALMNAMAPTTSHR
SCHEMBL2366009 0.88 ABL1 (0.38) HTTLMNAMAPTTSHRTP53
SCHEMBL2366954 0.86 CFTR (0.40) HTTKMT2ALMNAMAPTTSHR
SCHEMBL2366410 0.86 ABL1 (0.45) KMT2ALMNAMAPTTP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 HTT 1580/4885KMT2A 800/4885LMNA 3668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.